Risk of progression of a 6MPI to CIN2+ or CIN3+ associated with the same HPV type.

<div><p><b>2a. CIN2+</b></p> <p><b>2b. CIN3+</b></p> <p>Kaplan–Meier Estimates of Cumulative Risk (%) of Developing CIN2+ Lesions (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0079260#pone-0079260-g002" target="_blank">Figure 2a</a>) or CIN3+ Lesions (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0079260#pone-0079260-g002" target="_blank">Figure 2b</a>) Associated with the Same HPV Type Were Calculated for HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, Other Oncogenic HPV Types and Non-Oncogenic HPV Types</p></div

Summary according to HPV type of prevalence in 6MPI, risk of progression to CIN3+ lesion and chance of clearance.

<div><p>Dark-shaded boxes: high prevalence (>10%), high risk of progression (HR >20) or low chance of clearance (HR <0.85)</p> <p>Medium-shaded boxes: medium prevalence (5–10%), medium risk of progression (HR 5–20) or medium chance of clearance (0.85-<0.95)</p> <p>Light-shaded boxes: low prevalence (<5%), low risk of progression (HR <5) or high chance of clearance (HR ≥0.95)</p> <p>Definitions of high, medium and low prevalence, risk of progression and chance of clearance are arbitrary and are based on the results of the present study.</p> <p>6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; HR: hazard ratio.</p></div

Cumulative chance of clearing a cervical HPV infection (prevalent and incident infections).

<div><p><b>3a. Duration of infection</b></p> <p><b>3b. HPV type (infection of any duration)</b></p> <p>Kaplan–Meier estimates of probability of clearance (%) were calculated for transient, less than 6-month persistent HPV infection (6MPI), 6MPI and overall (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0079260#pone-0079260-g003" target="_blank">Figure 3a</a>) or according the HPV types (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0079260#pone-0079260-g003" target="_blank">Figure 3b</a>): HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, other oncogenic HPV types and non-oncogenic HPV types.</p></div